LeMaitre Vascular, Inc. (LMAT) — Fair Value Analysis

Base-case fair value (P50): $83.29 · Current price: $82.38 · Verdict: Fairly Valued

The Verdict on LMAT

Our Monte Carlo simulations indicate that LEMAITRE VASCULAR INC (LMAT) is currently Fairly Valued. While the stock trades at $82.38, our median fair value (P50) stands at $83.29. This implies a +1.1% against the current price, aligning with our 'Fairly Valued' verdict. Investors should note this slight variance, but the core analysis suggests the market is largely reflecting LMAT's intrinsic worth based on thousands of simulated forward scenarios.

How LMAT stacks up against peers

LMAT demonstrates a strong quality tier relative to its sector (n/a). This robust operational and financial health provides a solid foundation, which is incorporated into our Monte Carlo valuation framework. Despite this strong fundamental quality, the current market price of $82.38 sits close to our $83.29 fair value, indicating that the market has already factored in much of LMAT's strengths. The +1.1% reflects this balanced outlook, where a company with strong fundamentals is trading at a price near its estimated intrinsic value.

What this means for investors

For investors considering LMAT, the current valuation suggests a limited immediate arbitrage opportunity. With the stock at $82.38 and our median fair value at $83.29, the +1.1% indicates that significant alpha from a pure valuation perspective may require patience or a shift in fundamental drivers. The 'Fairly Valued' verdict, driven by rigorous Monte Carlo analysis, points to LMAT as a company whose current price is largely aligned with its long-term intrinsic value. To explore the full probabilistic distribution, including detailed bear and bull case scenarios, and track LMAT's fair value as new fundamentals are released, sign up for a free FairCurve account.